1. Hu, Shuxian. Immunomodulatory Properties of Kappa Opioids and Synthetic Cannabinoids in HIV-1 Neuropathogenesis. JOURNAL OF
    NEUROIMMUNE PHARMACOLOGY, DEC 2011.
  2. Reus, Gislaine Z. Administration of cannabidiol and imipramine induces antidepressant-like effects in the forced swimming test and increases
    brain-derived neurotrophic factor levels in the rat amygdala. ACTA NEUROPSYCHIATRICA, OCT 2011.
  3. Lafuente, Hector. Cannabidiol Reduces Brain Damage and Improves Functional Recovery After Acute Hypoxia-Ischemia in Newborn Pigs.
    PEDIATRIC RESEARCH, SEP 2011.
  4. Neuroprotective Effects of Phytocannabinoid-Based Medicines in Experimental Models of Huntington's Disease Author(s): Sagredo Onintza;
    Pazos M. Ruth; Satta Valentina; et al. Source: JOURNAL OF NEUROSCIENCE RESEARCH Volume: 89 Issue: 9 Pages: 1509-1518 DOI: 10.1002
    /jnr.22682 Published: SEP 2011 Times Cited: 0 (from All Databases) [ View abstract ] [ Hide abstract ]
  5. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects Author(s): Russo Ethan B. Source: BRITISH
    JOURNAL OF PHARMACOLOGY Volume: 163 Issue: 7 Special Issue: SI Pages: 1344-1364 DOI: 10.1111/j.1476-5381.2011.01238.x Published:
    AUG 2011 Times Cited: 1 (from All Databases) [ View abstract ] [ Hide abstract ]
  6. Prospects for cannabinoid therapies in basal ganglia disorders Author(s): Fernandez-Ruiz Javier; Moreno-Martet Miguel; Rodriguez-Cueto
    Carmen; et al. Source: BRITISH JOURNAL OF PHARMACOLOGY Volume: 163 Issue: 7 Special Issue: SI Pages: 1365-1378 DOI: 10.1111/j.
    1476-5381.2011.01365.x Published: AUG 2011 Times Cited: 1 (from All Databases) [ View abstract ] [ Hide abstract ]
  7. The dual neuroprotective-neurotoxic profile of cannabinoid drugs Author(s): Sarne Yosef; Asaf Fadi; Fishbein Miriam; et al. Source: BRITISH
    JOURNAL OF PHARMACOLOGY Volume: 163 Issue: 7 Special Issue: SI Pages: 1391-1401 DOI: 10.1111/j.1476-5381.2011.01280.x Published:
    AUG 2011 Times Cited: 1 (from All Databases) [ View abstract ] [ Hide abstract ]
  8. Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice
    Author(s): Kozela Ewa; Lev Nirit; Kaushansky Nathali; et al. Source: BRITISH JOURNAL OF PHARMACOLOGY Volume: 163 Issue: 7 Special
    Issue: SI Pages: 1507-1519 DOI: 10.1111/j.1476-5381.2011.01379.x Published: AUG 2011
  9. PSYCHOTROPIC AND NONPSYCHOTROPIC CANNABIS DERIVATIVES INHIBIT HUMAN 5-HT3A RECEPTORS THROUGH A RECEPTOR
    DESENSITIZATION-DEPENDENT MECHANISM Author(s): Xiong W, Koo BN, Morton R, et al. Source: NEUROSCIENCE Volume: 184 Pages: 28-
    37 Published: JUN 16 2011
  10. Lim, M. P. Cannabidiol causes activated hepatic stellate cell death through a mechanism of endoplasmic reticulum stress-induced apoptosis.
    CELL DEATH & DISEASE, JUN 2011.
  11. Little, J. P. Therapeutic Potential of Cannabinoids in the Treatment of Neuroinflammation Associated with Parkinson's Disease. MINI-REVIEWS
    IN MEDICINAL CHEMISTRY, JUN 2011.
  12. Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress,
    and cell death Author(s): Mukhopadhyay P, Rajesh M, Horvath B, et al. Source: FREE RADICAL BIOLOGY AND MEDICINE Volume: 50 Issue:
    10 Pages: 1368-1381 Published: MAY 15 2011
  13. A synthetic cannabinoid, CP55940, inhibits lipopolysaccharide-induced cytokine mRNA expression in a cannabinoid receptor-independent
    mechanism in rat cerebellar granule cells Author(s): Chiba T, Ueno S, Obara Y, et al. Source: JOURNAL OF PHARMACY AND
    PHARMACOLOGY Volume: 63 Issue: 5 Pages: 636-647 Published: MAY 2011
  14. Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors
    Author(s): Perez-Rial S, Garcia-Gutierrez MS, Molina JA, et al. Source: NEUROBIOLOGY OF AGING Volume: 32 Issue: 4 Pages: 631-645
    Published: APR 2011
  15. Retinal Microglial Activation and Inflammation Induced by Amadori-Glycated Albumin in a Rat Model of Diabetes Author(s): Ibrahim AS, El-
    Remessy AB, Matragoon S, et al. Source: DIABETES Volume: 60 Issue: 4 Pages: 1122-1133 Published: APR 2011
  16. Cannabinoids: Occurrence and Medicinal Chemistry Author(s): Appendino G, Chianese G, Taglialatela-Scafati O Source: CURRENT
    MEDICINAL CHEMISTRY Volume: 18 Issue: 7 Pages: 1085-1099 Published: MAR 2011
  17. Neural correlates of verbal learning in adolescent alcohol and marijuana users Author(s): Schweinsburg AD, Schweinsburg BC, Nagel BJ, et al.
    Source: ADDICTION Volume: 106 Issue: 3 Pages: 564-573 Published: MAR 2011
  18. Subjective and Physiological Effects After Controlled Sativex and Oral THC Administration  Author(s): Karschner E. L.; Darwin W. D.; McMahon
    R. P.; et al.  Source: CLINICAL PHARMACOLOGY & THERAPEUTICS  Volume: 89   Issue: 3   Pages: 400-407   DOI: 10.1038/clpt.2010.318   
    Published: MAR 2011
  19. Dual Neuroprotective and Neurotoxic Effects of Cannabinoid Drugs in Vitro Author(s): Bologov Anastasia; Gafni Mikhal; Keren Ora; et al.
    Source: CELLULAR AND MOLECULAR NEUROBIOLOGY  Volume: 31   Issue: 2   Pages: 195-202   DOI: 10.1007/s10571-010-9604-y   
    Published: MAR 2011
  20. Distribution patterns of cannabinoid CB1 receptors in the hippocampus of APP(swe)/PS1(Delta E9) double transgenic mice Author(s): Kalifa S,
    Polston EK, Allard JS, et al. Source: BRAIN RESEARCH Volume: 1376 Pages: 94-100 Published: FEB 28 2011
  21. Acute and chronic cannabinoid extracts administration affects motor function in a CREAE model of multiple sclerosis Author(s): Buccellato E,
    Carretta D, Utan A, et al. Source: JOURNAL OF ETHNOPHARMACOLOGY Volume: 133 Issue: 3 Pages: 1033-1038 Published: FEB 16 2011
  22. Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania Author(s): Valvassori SS, Elias G, de
    Souza B, et al. Source: JOURNAL OF PSYCHOPHARMACOLOGY Volume: 25 Issue: 2 Pages: 274-279 Published: FEB 2011
  23. Endocannabinoid system protects against cryptogenic seizures Author(s): van Rijn Clementine M.; Perescis Martin F. J.; Vinogradova Lyudmila;
    et al.  Source: PHARMACOLOGICAL REPORTS  Volume: 63   Issue: 1   Pages: 165-168   Published: JAN-FEB 2011
  24. Role of Cannabinoids in Multiple Sclerosis Author(s): Zajicek John P.; Apostu Vicentiu I.  Source: CNS DRUGS  Volume: 25   Issue: 3   Pages:
    187-201   DOI: 10.2165/11539000-000000000-00000   Published: 2011
  25. Plasma Cannabinoid Pharmacokinetics following Controlled Oral Delta(9)-Tetrahydrocannabinol and Oromucosal Cannabis Extract
    Administration Author(s): Karschner EL, Darwin WD, Goodwin RS, et al. Source: CLINICAL CHEMISTRY Volume: 57 Issue: 1 Pages: 66-75
    Published: JAN 2011
  26. Cannabidiol Attenuates Cardiac Dysfunction, Oxidative Stress, Fibrosis, and Inflammatory and Cell Death Signaling Pathways in Diabetic
    Cardiomyopathy Author(s): Rajesh M, Mukhopadhyay P, Batkai S, et al. Source: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
    Volume: 56 Issue: 25 Pages: 2115-2125 Published: DEC 14 2010
  27. Cytoprotective effects of vitamin E homologues against glutamate-induced cell death in immature primary cortical neuron cultures:
    Tocopherols and tocotrienols exert similar effects by antioxidant function Author(s): Saito Y, Nishio K, Akazawa YO, et al. Source: FREE
    RADICAL BIOLOGY AND MEDICINE Volume: 49 Issue: 10 Pages: 1542-1549 Published: NOV 30 2010
  28. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia Author(s): Bossong
    Matthijs G.; Niesink Raymond J. M. Source: PROGRESS IN NEUROBIOLOGY  Volume: 92   Issue: 3   Pages: 370-385   DOI: 10.1016/j.
    pneurobio.2010.06.010   Published: NOV 2010
  29. Cannabidiol Induces Intracellular Calcium Elevation and Cytotoxicity in Oligodendrocytes Author(s): Mato S, Sanchez-Gomez MV, Matute C
    Source: GLIA Volume: 58 Issue: 14 Pages: 1739-1747 Published: NOV 2010 Times Cited: 0

  31. Cannabidiol protects retinal neurons by preserving glutamine synthetase activity in diabetes Author(s): El-Remessy AB, Khalifa Y, Ola S, et al.
    Source: MOLECULAR VISION Volume: 16 Issue: 160-62 Pages: 1487-1495 Published: AUG 4 2010
  32. Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract
    and THC Extract in Patients with Intractable Cancer-Related Pain Author(s): Johnson JR, Burnell-Nugent M, Lossignol D, et al. Source:
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT Volume: 39 Issue: 2 Pages: 167-179 Published: FEB 2010
  33. Treatment with cannabidiol reverses oxidative stress parameters, cognitive impairment and mortality in rats submitted to sepsis by cecal ligation
    and puncture Author(s): Cassol OJ, Comim CM, Silva BR, et al. Source: BRAIN RESEARCH Volume: 1348 Pages: 128-138 Published: AUG 12
    2010
  34. Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression Author(s): Rieder SA, Chauhan A, Singh U, et al. Source:
    IMMUNOBIOLOGY Volume: 215 Issue: 8 Pages: 598-605 Published: AUG 2010
  35. Endocannabinoids, FOXO and the metabolic syndrome: Redox, function and tipping point - The view from two systems Author(s): Nunn AVW,
    Guy GW, Bell JD Source: IMMUNOBIOLOGY Volume: 215 Issue: 8 Pages: 617-628 Published: AUG 2010
  36. Cannabinoids and experimental models of multiple sclerosis Author(s): Kubajewska I, Constantinescu CS Source: IMMUNOBIOLOGY Volume:
    215 Issue: 8 Pages: 647-657 Published: AUG 2010
  37. Protective Effects of the Synthetic Cannabinoids CP55,940 and JWH-015 on Rat Brain Mitochondria upon Paraquat Exposure Author(s): Velez-
    Pardo C, Jimenez-Del-Rio M, Lores-Arnaiz S, et al. Source: NEUROCHEMICAL RESEARCH Volume: 35 Issue: 9 Pages: 1323-1332 Published:
    SEP 2010
  38. Cannabis and Amyotrophic Lateral Sclerosis: Hypothetical and Practical Applications, and a Call for Clinical Trials Author(s): Carter GT, Abood
    ME, Aggarwal SK, et al. Source: AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE Volume: 27 Issue: 5 Pages: 347-356
    Published: AUG 2010
  39. Cannabidiol injected into the bed nucleus of the stria terminalis modulates baroreflex activity through 5-HT1A receptors Author(s): Alves FHF,
    Crestani CC, Gomes FV, et al. Source: PHARMACOLOGICAL RESEARCH Volume: 62 Issue: 3 Pages: 228-236 Published: SEP 2010
  40. Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis Author(s): Wolf
    SA, Bick-Sander A, Fabel K, et al. Source: CELL COMMUNICATION AND SIGNALING Volume: 8 Article Number: 12 Published: JUN 17 2010
  41. Modulation of the endocannabinoid system: Neuroprotection or neurotoxicity? Author(s): Fowler CJ, Rojo ML, Rodriguez-Gaztelumendi A
    Source: EXPERIMENTAL NEUROLOGY Volume: 224 Issue: 1 Special Issue: Sp. Iss. SI Pages: 37-47 Published: JUL 2010
  42. Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at
    reperfusion Author(s): Walsh SK, Hepburn CY, Kane KA, et al. Source: BRITISH JOURNAL OF PHARMACOLOGY Volume: 160 Issue: 5 Pages:
    1234-1242 Published: JUL 2010
  43. EFFECTS OF MARIJUANA AND DIAZEPAM ON LIPID PEROXIDATION, NA(+), K+ ATPASE, AND LEVELS OF GLUTATHIONE AND 5-HTP IN
    RAT BRAIN Author(s): Calderon GD, Esquivel GJ, Garcia EH, et al. Source: ACTA BIOLOGICA HUNGARICA Volume: 61 Issue: 2 Pages: 135-
    144 Published: JUN 2010
  44. The endocannabinoid system as a target for the treatment of neurodegenerative disease Author(s): Scotter EL, Abood ME, Glass M Source:
    BRITISH JOURNAL OF PHARMACOLOGY Volume: 160 Issue: 3 Pages: 480-498 Published: JUN 2010
  45. Effect of (-)-Delta(9)-tetrahydrocannabinoid on the hepatic redox state of mice Author(s): Pinto CE, Moura E, Serrao MP, et al. Source:
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH Volume: 43 Issue: 4 Pages: 325-329 Published: APR 2010
  46. Title: The endocannabinoid system as a target for the treatment of neuronal damage Author(s): Fernandez-Ruiz J, Garcia C, Sagredo O, et al.
    Source: EXPERT OPINION ON THERAPEUTIC TARGETS Volume: 14 Issue: 4 Pages: 387-404 Published: APR 2010
  47. Testicular toxicity in cannabis extract treated mice: association with oxidative stress and role of antioxidant enzyme systems Author(s): Mandal
    TK, Das NS Source: TOXICOLOGY AND INDUSTRIAL HEALTH Volume: 26 Issue: 1 Pages: 11-23 Published: FEB 2010
  48. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB2 and
    adenosine receptors Author(s): Castillo A, Tolon MR, Fernandez-Ruiz J, et al. Source: NEUROBIOLOGY OF DISEASE Volume: 37 Issue: 2
    Special Issue: Sp. Iss. SI Pages: 434-440 Published: FEB 2010
  49. Cannabidiol Displays Antiepileptiform and Antiseizure Properties In Vitro and In Vivo Author(s): Jones NA, Hill AJ, Smith I, et al. Source:
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Volume: 332 Issue: 2 Pages: 569-577 Published: FEB 2010
  50. Opposite Effects of Delta-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology Author(s): Bhattacharyya S,
    Morrison PD, Fusar-Poli P, et al. Source: NEUROPSYCHOPHARMACOLOGY Volume: 35 Issue: 3 Pages: 764-774 Published: FEB 2010
  51. Cannabinoids and Parkinson's Disease Author(s): Garcia-Arencibia M, Garcia C, Fernandez-Ruiz J Source: CNS & NEUROLOGICAL
    DISORDERS-DRUG TARGETS Volume: 8 Issue: 6 Pages: 432-439 Published: DEC 2009
  52. Beneficial Effects of a Cannabis sativa Extract Treatment on Diabetes-induced Neuropathy and Oxidative Stress Author(s): Comelli F, Bettoni I,
    Colleoni M, et al. Source: PHYTOTHERAPY RESEARCH Volume: 23 Issue: 12 Pages: 1678-1684 Published: DEC 2009
  53. BDNF regulates neuronal sensitivity to endocannabinoids Author(s): Maison P, Walker DJ, Walsh FS, et al. Source: NEUROSCIENCE LETTERS
    Volume: 467 Issue: 2 Pages: 90-94 Published: DEC 25 2009
  54. White matter integrity in adolescents with histories of marijuana use and binge drinking Author(s): Jacobus J, McQueeny T, Bava S, et al.
    Source: NEUROTOXICOLOGY AND TERATOLOGY Volume: 31 Issue: 6 Pages: 349-355 Published: NOV-DEC 2009
  55. Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis Author(s):
    Borrelli F, Aviello G, Romano B, et al. Source: JOURNAL OF MOLECULAR MEDICINE-JMM Volume: 87 Issue: 11 Pages: 1111-1121 Published:
    NOV 2009
  56. Therapeutic Time Window of Cannabidiol Treatment on Delayed Ischemic Damage via High-Mobility Group Box1-Inhibiting Mechanism Author
    (s): Hayakawa K, Irie K, Sano K, et al. Source: BIOLOGICAL & PHARMACEUTICAL BULLETIN Volume: 32 Issue: 9 Pages: 1538-1544
    Published: SEP 2009
  57. Imaging the Neural Effects of Cannabinoids: Current Status and Future Opportunities for Psychopharmacology Author(s): Bhattacharyya S,
    Crippa JA, Martin-Santos R, et al. Source: CURRENT PHARMACEUTICAL DESIGN Volume: 15 Issue: 22 Pages: 2603-2614 Published: AUG
    2009
  58. Cannabinoids for the treatment of dementia Author(s): Krishnan S, Cairns R, Howard R Source: COCHRANE DATABASE OF SYSTEMATIC
    REVIEWS Issue: 2 Article Number: CD007204 Published: 2009
  59. The Dietary Polyphenols trans-Resveratrol and Curcumin Selectively Bind Human CB1 Cannabinoid Receptors with Nanomolar Affinities and
    Function as Antagonists/Inverse Agonists Author(s): Seely KA, Levi MS, Prather PL Source: JOURNAL OF PHARMACOLOGY AND
    EXPERIMENTAL THERAPEUTICS Volume: 330 Issue: 1 Pages: 31-39 Published: JUL 2009
  60. Cannabidiol in Medicine: A Review of its Therapeutic Potential in CNS Disorders Author(s): Scuderi C, De Filippis D, Iuvone T, et al. Source:
    PHYTOTHERAPY RESEARCH Volume: 23 Issue: 5 Pages: 597-602 Published: MAY 2009
  61. Effect of delta-9-tetrahydrocannabinol on altered antioxidative enzyme defense mechanisms and lipid peroxidation in mice testes Author(s):
    Mandal TK, Das NS Source: EUROPEAN JOURNAL OF PHARMACOLOGY Volume: 607 Issue: 1-3 Pages: 178-187 Published: APR 1 2009
  62. Fungal biotransformations of cannabinoids: Potential for new effective drugs Author(s): Saxena S Source: CURRENT OPINION IN DRUG
    DISCOVERY & DEVELOPMENT Volume: 12 Issue: 2 Pages: 305-312 Published: MAR 2009
  63. Gene polymorphism of tetrahydrocannabinolic acid synthase in hemp Cannabis sativa L. Laboratory note Author(s): Wielgus K, Przewozna J,
    Szalata M Source: PRZEMYSL CHEMICZNY Volume: 87 Issue: 12 Pages: 1201-1202 Published: DEC 2008
  64. Neuroprotective effects of cannabidiol in endotoxin-induced uveitis: critical role of p38 MAPK activation Author(s): El-Remessy AB, Tang Y,
    Zhu G, et al. Source: MOLECULAR VISION Volume: 14 Issue: 256 Pages: 2190-2203 Published: DEC 3 2008
  65. Fungal biotransformations of cannabinoids: Potential for new effective drugs Author(s): Saxena S Source: IDRUGS Volume: 12 Issue: 2 Pages:
    305-312 Published: MAR 2009
  66. Cannabidiol Attenuates Cisplatin-Induced Nephrotoxicity by Decreasing Oxidative/Nitrosative Stress, Inflammation, and Cell Death Author(s):
    Pan H, Mukhopadhyay P, Rajesh M, et al. Source: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Volume: 328
    Issue: 3 Pages: 708-714 Published: MAR 2009
  67. Title: Cannabidiol Targets Mitochondria to Regulate Intracellular Ca2+ Levels Author(s): Ryan D, Drysdale AJ, Lafourcade C, et al. Source:
    JOURNAL OF NEUROSCIENCE Volume: 29 Issue: 7 Pages: 2053-2063 Published: FEB 18 2009
  68. Cannabidiol: A Promising Drug for Neurodegenerative Disorders ? Author(s): Iuvone T, Esposito G, De Filippis D, et al. Source: CNS
    NEUROSCIENCE & THERAPEUTICS Volume: 15 Issue: 1 Pages: 65-75 Published: 2009
  69. 2-Arachidonoylglycerol Elicits Neuroprotective Effects on Excitotoxically Lesioned Dentate Gyrus Granule Cells via Abnormal-Cannabidiol-
    Sensitive Receptors on Microglial Cells Author(s): Kreutz S, Koch M, Bottger C, et al. Source: GLIA Volume: 57 Issue: 3 Pages: 286-294
    Published: FEB 2009
  70. Antioxidant Therapy in Alzheimer's Disease: Theory and Practice Author(s): Aliev G, Obrenovich ME, Reddy VP, et al. Source: MINI-REVIEWS
    IN MEDICINAL CHEMISTRY Volume: 8 Issue: 13 Pages: 1395-1406 Published: NOV 2008
  71. Cannabidiol prevents a post-ischemic injury progressively induced by cerebral ischemia via a high-mobility group box1-inhibiting mechanism
    Author(s): Hayakawa K, Mishima K, Irie K, et al. Source: NEUROPHARMACOLOGY Volume: 55 Issue: 8 Pages: 1280-1286 Published: DEC 2008
  72. Post-ischemic brain damage: the endocannabinoid system in the mechanisms of neuronal death Author(s): Pellegrini-Giampietro DE,
    Mannaioni G, Bagetta G Source: FEBS JOURNAL Volume: 276 Issue: 1 Pages: 2-12 Published: JAN 2009
  73. Mediation of Cannabidiol Anti-inflammation in the Retina by Equilibrative Nucleoside Transporter and A(2A) Adenosine Receptor Author(s):
    Liou GI, Auchampach JA, Hillard CJ, et al. Source: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE Volume: 49 Issue: 12 Pages:
    5526-5531 Published: DEC 2008
  74. The tools of the trade" - An overview of the pharmacology of the endocannabinoid system Author(s): Fowler CJ Source: CURRENT
    PHARMACEUTICAL DESIGN Volume: 14 Issue: 23 Pages: 2254-2265 Published: AUG 2008
  75. Mechanisms of control of neuron survival by the endocannabinoid system Author(s): Galve-Roperh I, Aguado T, Palazuelos J, et al. Source:
    CURRENT PHARMACEUTICAL DESIGN Volume: 14 Issue: 23 Pages: 2279-2288 Published: AUG 2008
  76. The role of the endocannabinoid system in Alzheimer's disease: Facts and hypotheses Author(s): Bisogno T, Di Marzo V Source: CURRENT
    PHARMACEUTICAL DESIGN Volume: 14 Issue: 23 Pages: 2299-2305 Published: AUG 2008
  77. The endocannabinoid system in amyotrophic lateral sclerosis Author(s): Bilsland LG, Greensmith L Source: CURRENT PHARMACEUTICAL
    DESIGN Volume: 14 Issue: 23 Pages: 2306-2316 Published: AUG 2008
  78. Role of cannabinoids and endocannabinoids in cerebral ischemia Author(s): Hillard CJ Source: CURRENT PHARMACEUTICAL DESIGN
    Volume: 14 Issue: 23 Pages: 2347-2361 Published: AUG 2008
  79. Charcot-Marie-Tooth disease Author(s): Carter GT, Weiss MD, Han JJ, et al. Source: CURRENT TREATMENT OPTIONS IN NEUROLOGY
    Volume: 10 Issue: 2 Pages: 94-102 Published: MAR 2008
  80. JunD is involved in the antiproliferative effect of Delta(9)-tetrahydrocannabinol on human breast cancer cells Author(s): Caffarel MM, Moreno-
    Bueno G, Cerutti C, et al. Source: ONCOGENE Volume: 27 Issue: 37 Pages: 5033-5044 Published: AUG 28 2008 Times Cited: 4
  81. The cannabinoid CP55,940 prolongs survival and improves locomotor activity in Drosophila melanogaster against paraquat: Implications in
    Parkinson's disease Author(s): Jimenez-Del-Rio M, Daza-Restrepo A, Velez-Pardo C Source: NEUROSCIENCE RESEARCH Volume: 61 Issue: 4
    Pages: 404-411 Published: AUG 2008 Times Cited: 6
  82. Title: The protective effect of dexanabinol (HU-211) on nitric oxide and cysteine protease-mediated neuronal death in focal cerebral ischemia
    Author(s): Durmaz R, Ozden H, Kanbak G, et al. Source: NEUROCHEMICAL RESEARCH Volume: 33 Issue: 9 Pages: 1683-1691 Published: SEP
    2008
  83. Effect of cannabidiol on sepsis-induced motility disturbances in mice: involvement of CB1 receptors and fatty acid amide hydrolase Author(s):
    De Filippis D, Iuvone T, D'Amico A, et al. Source: NEUROGASTROENTEROLOGY AND MOTILITY Volume: 20 Issue: 8 Pages: 919-927
    Published: AUG 2008 Times Cited: 12
  84. Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice Author(s): Capasso R, Borrelli F, Aviello G,
    et al. Source: BRITISH JOURNAL OF PHARMACOLOGY Volume: 154 Issue: 5 Pages: 1001-1008 Published: JUL 2008 Times Cited: 12
  85. Cannabidiol: A prion therapy for mice? Author(s): Dicou E Source: JOURNAL OF NEUROSCIENCE RESEARCH Volume: 86 Issue: 6 Pages:
    1417-1418 Published: MAY 1 2008
  86. Clinical endocannabinoid deficiency (CECD) - Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable
    bowel syndrome and other treatment-resistant conditions? Author(s): Russo EB Source: NEUROENDOCRINOLOGY LETTERS Volume: 29 Issue:
    2 Pages: 192-200
  87. Title: A role for p53 in the regulation of lysosomal permeability by Delta(9)-tetrahydrocannabinol in rat cortical neurones: implications for
    neurodegeneration Author(s): Gowran A, Campbell VA Source: JOURNAL OF NEUROCHEMISTRY Volume: 105 Issue: 4 Pages: 1513-1524
  88. Khaspekov LG, Bobrov MY The endocannabinoid system and its protective role in ischemic and cytotoxic injuries of brain neurons.
    NEUROCHEMICAL JOURNAL 1(2):93-112.
  89. Durmaz R, Ozsandik A, Sahinturk V, et al. Dexanabinol prevents development of vasospasm in the rat femoral artery model.  NEUROSURGICAL
    REVIEW 31(2):215-223 (2008)
  90. Woelkart K, Salo-Ahen OMH, Bauer R. CB receptor ligands from plants CURRENT TOPICS IN MEDICINAL CHEMISTRY 8(3):173-186 (2008)
  91. Bindukumar B, Mahajan SD, Reynolds JL, et al. Genomic and proteomic analysis of the effects of cannabinoids on normal human astrocytes.
    BRAIN RESEARCH 1191:1-11.
  92. Senn R, Keren O, Hefetz A, et al. Long-term cognitive deficits induced by a single, extremely low dose of tetrahydrocannabinol (THC):
    Behavioral, pharmacological and biochemical studies in mice PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR. 88:230-237
  93. Rock EM, Limebeer CL, Mechoulam R, et al.  The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a
    lithium-paired context in the rat  PSYCHOPHARMACOLOGY Volume: 196 Issue: 3 Pages: 389-395 Published: 2008
  94. Juckel G, Roser P, Nadulski T. et al., Acute effects of Delta(9)-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked
    mismatch negativity  SCHIZOPHRENIA RESEARCH Volume: 97 Issue: 1-3 Pages: 109-117 Published: 2007
  95. Zani A, Braida D, Capurro V, et al. Delta(9)-Tetrahydrocannabinol (THC) and AM 404 protect against cerebral ischaemia in gerbils through a
    mechanism involving cannabinoid and opioid receptors BRITISH JOURNAL OF PHARMACOLOGY 152 (8): 1301-1311 DEC 2007
  96. Dowling GJ, Weiss SRB, Condon TP Drugs of abuse and the aging brain NEUROPSYCHOPHARMACOLOGY 33 (2): 209-218 JAN 2008
  97. Downer EJ, Gowran A, Campbell VA A comparison of the apoptotic effect of Delta(9)-tetrahydrocannabinol in the neonatal and adult rat
    cerebral cortex BRAIN RESEARCH 1175: 39-47 OCT 17 2007
  98. Campbell VA, Gowran A Alzheimer's disease; taking the edge off with cannabinoids? BRITISH JOURNAL OF PHARMACOLOGY 152 (5): 655-
    662 NOV 2007
  99. Kim SR, Chung YC, Chung ES, et al. Roles of transient receptor potential vanilloid subtype 1 and cannabinoid type 1 receptors in the brain:
    Neuroprotection versus neurotoxicity MOLECULAR NEUROBIOLOGY 35 (3): 245-254 JUN 2007
  100. Mechoulam R, Shohami E Endocannabinoids and traumatic brain injury MOLECULAR NEUROBIOLOGY 36 (1): 68-74 AUG 2007
  101. Sagredo O, Garcia-Arencibia M, de Lago E, et al. Cannabinoids and neuroprotection in basal ganglia disorders MOLECULAR
    NEUROBIOLOGY 36 (1): 82-91 AUG 2007
  102. Centonze D, Rossi S, Finazzi-Agro A, et al. The (endo)cannabinoid system in multiple sclerosis and amyotrophic lateral sclerosis
    INTERNATIONAL REVIEW OF NEUROBIOLOGY 82: 171-186 2007
  103. Reinhard C, Wolffgramm J Abstinence-enduring behavioural alterations as a consequence of long-term voluntary consumption of low doses of
    MDMA and THC in rats NEUROLOGY PSYCHIATRY AND BRAIN RESEARCH 12 (2): 75-84 2005
  104. Russo EB History of cannabis and its preparations in saga, science, and sobriquet CHEMISTRY & BIODIVERSITY 4 (8): 1614-1648 2007
  105. Taura F, Sirikantaramas S, Shoyama Y, et al. Phytocannabinoids in Cannabis sativa: Recent studies on Biosynthetic enzymes CHEMISTRY &
    BIODIVERSITY 4 (8): 1649-1663 2007
  106. Costa B On the pharmacological properties of Delta(9)-tetrahydrocannabinol (THC) CHEMISTRY & BIODIVERSITY 4 (8): 1664-1677 2007
  107. Mechoulam R, Peters M, Murillo-Rodrigiiez E, et al. Cannabidiol - Recent advances CHEMISTRY & BIODIVERSITY 4 (8): 1678-1692 2007
  108. Russo EB, Geoffrey WG, Robson PJ Cannabis, pain, and sleep: Lessons from therapeutic clinical trials of Sativex((R)), a cannabis-based
    medicine CHEMISTRY & BIODIVERSITY 4 (8): 1729-1743 2007 Times Cited: 0
  109. Huestis MA Human cannabinoid pharmacokinetics CHEMISTRY & BIODIVERSITY 4 (8): 1770-1804 2007
  110. Parrott AC, Milani RM, Gouzoulis-Mayfrank E, et al. Cannabis and ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their
    neuropsychobiological interactions in recreational users JOURNAL OF NEURAL TRANSMISSION 114 (8): 959-968 AUG 2007
  111. Dagon Y, Avraham Y, Link G, et al. The synthetic cannabinoid HU-210 attenuates neural damage in diabetic mice and hyperglycemic
    pheochromocytoma PC12 cells NEUROBIOLOGY OF DISEASE 27 (2): 174-181 AUG 2007
  112. Sagredo O, Ramos JA, Decio A, et al. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms
    independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A(2A) receptors EUROPEAN JOURNAL OF NEUROSCIENCE 26
    (4): 843-851 AUG 2007
  113. Rajesh M, Mukhopadhyay P, Batkai S, et al. Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier
    disruption AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY 293 (1): H610-H619 JUL 2007
  114. Campolongo P, Trezza V, Cassano T, et al. Perinatal exposure to delta-9-tetrahydrocannabinol causes enduring cognitive deficits associated
    with alteration of cortical gene expression and neurotransmission in rats ADDICTION BIOLOGY 12 (3-4): 485-495 SEP 2007
  115. Taura F, Sirikantaramas S, Shoyama Y, et al. Cannabidiolic-acid synthase, the chemotype-determining enzyme in the fiber-type Cannabis
    sativa FEBS LETTERS 581 (16): 2929-2934 JUN 26 2007
  116. Youssef FF, Hormuzdi SG, Irving AJ, et al. Cannabinoid modulation of neuronal function after oxygen/glucose deprivation in area CA1 of the
    rat hippocampus NEUROPHARMACOLOGY 52 (6): 1327-1335 MAY 2007
  117. Hermann D, Sartorius A, Welzel H, et al. Dorsolateral prefrontal cortex N-acetylaspartate/total creatine (NAA/tCr) loss in male recreational
    cannabis users BIOLOGICAL PSYCHIATRY 61 (11): 1281-1289 JUN 1 2007
  118. Maccarrone M, Battista N, Centonze D The endocannabinoid pathway in Huntington's disease: A comparison with other neurodegenerative
    diseases PROGRESS IN NEUROBIOLOGY 81 (5-6): 349-379 APR 2007
  119. Martinez-Gras I, Hoecnika J, Perez-Hernandez E, et al. Endocannabinoid system and CNR1 gene polymorphisms in schizophrenia and
    addictive disorders ACTAS ESPANOLAS DE PSIQUIATRIA 35 (2): 122-129 MAR-APR 2007 Times Cited: 0
  120. Giannini L, Mastroianni R, Mariottini C, et al. Activation of cannabinoid receptors reduces allergen-induced oxidative stress damage during
    asthma-like reaction in sensitised guinea-pigs INFLAMMATION RESEARCH 56: S11-S12 Suppl. 1 APR 2007
  121. Hayakawa K, Mishima K, Nozako M, et al. Repeated treatment with cannabidiol but not Delta(9)-tetrahydrocannabinol has a neuroprotective
    effect without the development of tolerance NEUROPHARMACOLOGY 52 (4): 1079-1087 MAR 2007
  122. Crandall J, Matragoon S, Khalifa YM, et al. Neuroprotective and Intraocular pressure-lowering effects of (-)Delta 9-tetrahydrocannabinol in a rat
    model of glaucoma OPHTHALMIC RESEARCH 39 (2): 69-75 2007
  123. Costa B, Trovato AE, Comelli F, et al. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat
    chronic inflammatory and neuropathic pain EUROPEAN JOURNAL OF PHARMACOLOGY 556 (1-3): 75-83 FEB 5 2007
  124. Garcia-Arencibia M, Gonzalez S, de Lago E, et al. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's
    disease: Importance of antioxidant and cannabinoid receptor-independent properties BRAIN RESEARCH 1134 (1): 162-170 FEB 23 2007
  125. Kessiova M, Alexandrova A, Georgieva A, et al. In vitro effects of CB1 receptor ligands on lipid peroxidation and antioxidant defense systems in
    the rat brain PHARMACOLOGICAL REPORTS 58 (6): 870-875 NOV-DEC 2006
  126. Tsvetanova E, Kessiova M, Alexandrova A, et al. In vivo effects of CB1 receptor ligands on lipid peroxidation and antioxidant defense systems
    in the brain of healthy and ethanol-treated rats PHARMACOLOGICAL REPORTS 58 (6): 876-883 NOV-DEC 2006
  127. Gilbert GL, Kim HJ, Waataja JJ, et al. Delta(9)-Tetrahydrocannabinol protects hippocampal neurons from excitotoxicity BRAIN RESEARCH
    1128 (1): 61-69 JAN 12 2007
  128. Kreutz S, Koch M, Ghadban C, et al. Cannabinoids and neuronal damage: Differential effects of THC, AEA and 2-AG on activated microglial
    cells and degenerating neurons in excitotoxically lesioned rat organotypic hippocampal slice cultures EXPERIMENTAL NEUROLOGY 203 (1):
    246-257 JAN 2007
  129. del Valle AA Implication of cannabinoids in neurological diseases CELLULAR AND MOLECULAR NEUROBIOLOGY 26 (4-6): 579-591 JUL-AUG
    2006
  130. Perez J Combined cannabinoid therapy via an oromucosal spray DRUGS OF TODAY 42 (8): 495-503 AUG 2006
  131. Pacher P, Batkai S, Kunos G The endocannabinoid system as an emerging target of pharmacotherapy PHARMACOLOGICAL REVIEWS 58 (3):
    389-462 SEP 2006
  132. Massi P, Vaccani A, Bianchessi S, et al. The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma
    cells CELLULAR AND MOLECULAR LIFE SCIENCES 63 (17): 2057-2066 SEP 2006
  133. Bilsland LG, Dick JRT, Pryce G, et al. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression
    in SOD1 mice FASEB JOURNAL 20 (7): doi:10.1096/fj.05-4743fje MAY 2006
  134. Ligresti A, Moriello AS, Starowicz K, et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast
    carcinoma JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 318 (3): 1375-1387 SEP 2006
  135. Murillo-Rodriguez E, Millan-Aldaco D, Palomero-Rivero M, et al. Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats FEBS
    LETTERS 580 (18): 4337-4345 AUG 7 2006
  136. Galve-Roperh I, Aguado T, Rueda D, et al. Endocannabinoids: A new family of lipid mediators involved in the regulation of neural cell
    development CURRENT PHARMACEUTICAL DESIGN 12 (18): 2319-2325 2006
  137. Oz M Receptor-independent actions of cannabinoids on cell membranes: Focus on endocannabinoids PHARMACOLOGY & THERAPEUTICS
    111 (1): 114-144 JUL 2006
  138. Panikashvili D, Shein NA, Mechoularn R, et al. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits
    mRNA expression of proinflammatory cytokines NEUROBIOLOGY OF DISEASE 22 (2): 257-264 MAY 2006
  139. Pozzoli G, Tringali G, Vairano M, et al. Cannabinoid agonist WIN55,212-2 induces apoptosis in cerebellar granule CELLS via activation of the
    CB1 receptor and downregulation of bci-x(L) gene expression JOURNAL OF NEUROSCIENCE RESEARCH 83 (6): 1058-1065 MAY 1 2006
  140. Zuardi AW, Crippa JAS, Hallak JEC, et al. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug BRAZILIAN JOURNAL OF
    MEDICAL AND BIOLOGICAL RESEARCH 39 (4): 421-429 APR 2006
  141. Bahr BA, Karanian DA, Makanji SS, et al. Targeting the endocannabinoid system in treating brain disorders EXPERT OPINION ON
    INVESTIGATIONAL DRUGS 15 (4): 351-365 APR 2006
  142. Gouzoulis-Mayfrank E, Daumann J The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview JOURNAL
    OF PSYCHOPHARMACOLOGY 20 (2): 188-193 MAR 2006
  143. Whan LB, West MCL, McClure N, et al. Effects of delta-9-tetrahydrocannabinol, the primary psychoactive cannabinoid in marijuana, on human
    sperm function in vitro FERTILITY AND STERILITY 85 (3): 653-660 MAR 2006
  144. Ben-Shabat S, Hanus LO, Katzavian G, et al. New cannabidiol derivatives: Synthesis, binding to cannabinoid receptor, and evaluation of their
    antiinflammatory activity JOURNAL OF MEDICINAL CHEMISTRY 49 (3): 1113-1117 FEB 9 2006
  145. Fadda P, Robinson L, Fratta W, et al. Scopolamine and MK801-induced working memory deficits in rats are not reversed by CBD-rich cannabis
    extracts BEHAVIOURAL BRAIN RESEARCH 168 (2): 307-311 APR 3 2006
  146. Kathmann M, Flau K, Redmer A, et al. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors NAUNYN-SCHMIEDEBERGS
    ARCHIVES OF PHARMACOLOGY 372 (5): 354-361 FEB 2006
  147. Esposito G, De Filippis D, Carnuccio R, et al. The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein
    hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells JOURNAL OF MOLECULAR MEDICINE-JMM 84 (3): 253-258
    MAR 2006
  148. Russo E, Guy GW A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol MED
    HYPOTHESES 66 (2): 234-246 2006
  149. El-Remessy AB, Al-Shabrawey M, Khalifa Y, et al. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental
    diabetes AM J PATHOL 168 (1): 235-244 JAN 2006
  150. Grant I, Cahn BR Cannabis and endocannabinoid modulators: Therapeutic promises and challenges CLIN NEUROSCI RES 5 (2-4): 185-199
    NOV 2005
  151. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up J
    NEUROL NEUROSUR PS 76 (12): 1664-1669 DEC 2005
  152. Russo EB, Burnett A, Hall B, et al. Agonistic properties of cannabidiol at 5-HT1a receptors NEUROCHEM RES 30 (8): 1037-1043 AUG 2005
  153. Long LE, Malone DT, Taylor DA The pharmacological actions of cannabidiol DRUG FUTURE 30 (7): 747-753 JUL 2005
  154. Schneider U, Seifert I, Karst M, et al. The endogenous cannabinoid system. Therapeutic implications for neurologic and psychiatric disorders
    NERVENARZT 76 (9): 1062-+ SEP 2005
  155. Moussaieff A, Fride E, Amar Z, et al. The Jerusalem Balsam: From the Franciscan monastery in the old city of Jerusalem to Martindale 33 J
    ETHNOPHARMACOL 101 (1-3): 16-26 OCT 3 2005
  156. van der Stelt M, Di Marzo V Cannabinoid receptors and their role in neuroprotection NEUROMOL MED 7 (1-2): 37-50 2005
  157. Goncharov I, Weiner L, Vogel Z Delta 9-tetrahydrocannabinol increases C6 glioma cell death produced by oxidative stress NEUROSCIENCE
    134 (2): 567-574 2005
  158. Trebst C, Stangel M Cannabinoids in multiple sclerosis - Therapeutically reasonable? FORTSCHR NEUROL PSYC 73 (8): 463-469 AUG 2005
  159. Lambert DM, Fowler CJ The endocannabinoid system: Drug targets, lead compounds, and potential therapeutic applications J MED CHEM 48
    (16): 5059-5087 AUG 11 2005
  160. Teare L, Zajicek J The use of cannabinoids in multiple sclerosis EXPERT OPIN INV DRUG 14 (7): 859-869 JUL 2005
  161. Hamelink C, Hampson A, Wink DA, et al. Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced
    neurotoxicity J PHARMACOL EXP THER 314 (2): 780-788 AUG 2005
  162. Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: Role of oxidative stress CURR DRUG
    TARGETS 6 (4): 511-524 JUN 2005
  163. Jackson SJ, Diemel LT, Pryce G, et al. Cannabinoids and neuroprotection in CNS inflammatory disease J NEUROL SCI 233 (1-2): 21-25 JUN 15
    2005
  164. Zhuang SY, Bridges D, Grigorenko E, et al. Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-
    sensitive stores NEUROPHARMACOLOGY 48 (8): 1086-1096 JUN 2005
  165. Begg M, Pacher P, Batkai S, et al. Evidence for novel cannabinoid receptors PHARMACOL THERAPEUT 106 (2): 133-145 MAY 2005
  166. Mishima K, Hayakawa K, Abe K, et al. Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine(1A) receptor-dependent
    mechanism STROKE 36 (5): 1071-1076 MAY 2005
  167. Chen J, Lee CT, Errico S, et al. Protective effects of Delta(9)-tetrahydrocannabinol against N-methyl-D-aspartate-induced AF5 cell death MOL
    BRAIN RES 134 (2): 215-225 APR 4 2005
  168. Lastres-Becker I, Molina-Holgado F, Ramos JA, et al. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in
    vitro: Relevance to Parkinson's disease NEUROBIOL DIS 19 (1-2): 96-107 JUN-JUL 2005
  169. Panikashvili D, Mechoulam R, Beni SM, et al. CB1 cannabinoid receptors are involved in neuroprotection via NF-kappa B inhibition J CEREBR
    BLOOD F MET 25 (4): 477-484 APR 2005
  170. Kim SH, Won SJ, Mao XO, et al. Involvement of protein kinase A in cannabinoid receptor-mediated protection from oxidative neuronal injury J
    PHARMACOL EXP THER 313 (1): 88-94 APR 2005
  171. Hanus LO, Tchilibon S, Ponde DE, et al. Enantiomeric cannabidiol derivatives: synthesis and binding to cannabinoid receptors ORG BIOMOL
    CHEM 3 (6): 1116-1123 2005
  172. Pertwee RG Pharmacological and therapeutic targets for Delta(9)-tetrahydrocannabinol and cannabidiol EUPHYTICA 140 (1-2): 73-82 2004
  173. Molina-Holgado F, Pinteaux E, Heenan L, et al. Neuroprotective effects of the synthetic cannabinoid HU-210 in primary cortical neurons are
    mediated by phosphatidylinositol 3-kinase/AKT signaling MOL CELL NEUROSCI 28 (1): 189-194 JAN 2005
  174. Fadda P, Robinson L, Fratta W, et al. Differential effects of THC or CBD-rich cannabis extracts on working memory in rats
    NEUROPHARMACOLOGY 47 (8): 1170-1179 DEC 2004
  175. Gonzalez R, Rippeth JD, Carey CL, et al. Neurocognitive performance of methamphetamine users discordant for history of marijuana exposure
    DRUG ALCOHOL DEPEN 76 (2): 181-190 NOV 11 2004
  176. Juttler E, Potrovita I, Tarabin V, et al. The cannabinoid dexanabinol is an inhibitor of the nuclear factor-kappa B (NF-kappa B)
    NEUROPHARMACOLOGY 47 (4): 580-592 SEP 2004
  177. Venderova K, Ruzicka E, Vorisek V, et al. Survey on cannabis use in Parkinson's disease: Subjective improvement of motor symptoms
    MOVEMENT DISORD 19 (9): 1102-1106 SEP 2004
  178. Carter GT, Weydt P, Kyashna-Tocha M, et al. Medicinal cannabis: Rational guidelines for dosing IDRUGS 7 (5): 464-470 MAY 2004
  179. Sarne Y, Keren O Are cannabinoid drugs neurotoxic or neuroprotective? MED HYPOTHESES 63 (2): 187-192 2004
  180. Russo EB, Merzouki A, Mesa JM, et al. Cannabis improves night vision: a case study of dark adaptometry and scotopic sensitivity in kif smokers of
    the Rif mountains of northern Morocco J ETHNOPHARMACOL 93 (1): 99-104 JUL 2004
  181. Biegon A Cannabinoids as neuroprotective agents in traumatic brain injury CURR PHARM DESIGN 10 (18): 2177-2183 2004
  182. Carracedo A, Geelen MJH, Diez M, et al. Ceramide sensitizes astrocytes to oxidative stress: protective role of cannabinoids BIOCHEM J 380:
    435-440 Part 2 JUN 1 2004
  183. Russo EB Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia,
    irritable bowel syndrome and other treatment-resistant conditions? NEUROENDOCRINOL LETT 25 (1-2): 31-39 FEB-APR 2004
  184. McQueen DS, Bond SM, Smith PJW, et al. Cannabidiol lacks the vanilloid VR1-mediated vasorespiratory effects of capsaicin and anandarnide
    in anaesthetised rats EUR J PHARMACOL 491 (2-3): 181-189 MAY 3 2004
  185. Morley KC, Li KM, Hunt GE, et al. Cannabinoids prevent the acute hyperthermia and partially protect against the 5-HT depleting effects of
    MDMA ("Ecstasy") in rats NEUROPHARMACOLOGY 46 (7): 954-965 JUN 2004
  186. Tomida I, Pertwee RG, Azuara-Blanco A Cannabinoids and glaucoma BRIT J OPHTHALMOL 88 (5): 708-712 MAY 1 2004
  187. Liang D, Dawson TM, Dawson VL What have genetically engineered mice taught us about ischemic injury? CURR MOL MED 4 (2): 207-225
    MAR 2004
  188. Raman C, McAllister SD, Rizvi G, et al. Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid
    AMYOTROPH LATERAL SC 5 (1): 33-39 MAR 2004
  189. Iuvone T, Esposito G, Esposito R, et al. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-
    amyloid-induced toxicity in PC12 cells J NEUROCHEM 89 (1): 134-141 APR 2004
  190. Costa B, Colleoni M, Conti S, et al. Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute
    carrageenan-induced inflammation in the rat paw N-S ARCH PHARMACOL 369 (3): 294-299 MAR 2004
  191. Drysdale AJ, Platt B Cannabinoids: Mechanisms and therapeutic applications in the CNS CURR MED CHEM 10 (24): 2719-2732 DEC 2003
  192. Berger C, Schmid PC, Schabitz WR, et al. Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral
    ischemia? J NEUROCHEM 88 (5): 1159-1167 MAR 2004
  193. Crippa JAD, Zuardi AW, Garrido GEJ, et al. Effects of cannabidiol (CBD) on regional cerebral blood flow NEUROPSYCHOPHARMACOL 29 (2):
    417-426 FEB 2004
  194. Mauler F, Horvath E, De Vry J, et al. BAY 38-7271: A novel highly selective and highly potent cannabinoid receptor agonist for the treatment of
    traumatic brain injury CNS DRUG REV 9 (4): 343-358 WIN 2003
  195. Parker LA, Kwiatkowska M, Burton P, et al. Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew)
    PSYCHOPHARMACOLOGY 171 (2): 156-161 JAN 2004
  196. Nilsson O, Jacobsson SOP, Fowler CJ Cannabinoid CB1 receptor activation does not prevent the toxicity of glutamate towards embryonic chick
    telencephalon primary cultures COMP BIOCHEM PHYS C 136 (3): 245-251 NOV 2003
  197. El-Remessy AB, Khalil IE, Matragoon S, et al. Neuroprotective effect of(-)Delta(9)-tetrahydrocannabinol and cannabidiol in N-methyl-D-
    aspartate-induced retinal neurotoxicity - Involvement of peroxynitrite AM J PATHOL 163 (5): 1997-2008 NOV 2003
  198. Downer EJ, Fogarty MP, Campbell VA Tetrahydrocannabinol-induced neurotoxicity depends on CB1 receptor-mediated c-Jun N-terminal kinase
    activation in cultured cortical neurons BRIT J PHARMACOL 140 (3): 547-557 OCT 2003
  199. Parker LA, Mechoulam R Cannabinoid agonists and antagonists modulate lithium-induced conditioned gaping in rats INTEGR PHYS BEH SCI
    38 (2): 133-145 APR-JUN 2003
  200. Pryce G, Ahmed Z, Hankey DJR, et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis BRAIN 126: 2191-2202 Part 10
    OCT 2003
  201. Mandel S, Grunblatt E, Riederer P, et al. Neuroprotective strategies in Parkinson's disease - An update on progress CNS DRUGS 17 (10): 729-
    762 2003
  202. Gilgun-Sherki Y, Melamed E, Mechoulam R, et al. The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-
    hydroxydopamine-lesioned rats PHARMACOL TOXICOL 93 (2): 66-70 AUG 2003
  203. Molina-Holgado F, Pinteaux E, Moore JD, et al. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective
    actions of cannabinoids in neurons and glia J NEUROSCI 23 (16): 6470-6474 JUL 23 2003
  204. Carter GT, Krivickas LS, Weydt P, et al. Drug therapy for amyotrophic lateral sclerosis: Where are we now? IDRUGS 6 (2): 147-153 FEB 2003
  205. van der Stelt M, Hansen HH, Veldhuis WB, et al. Biosynthesis of endocannabinoids and their modes of action in neurodegenerative diseases
    NEUROTOX RES 5 (3): 183-199 2003
  206. Lastres-Becker I, Bizat N, Boyer F, et al. Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection
    of malonate NEUROREPORT 14 (6): 813-816 MAY 6 2003
  207. Iversen L Cannabis and the brain BRAIN 126: 1252-1270 Part 6 JUN 2003
  208. Croxford JL, Miller SD Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R(+)WIN55,212 J CLIN INVEST
    111 (8): 1231-1240 APR 2003
  209. Parker LA, Mechoulam R, Schlievert C, et al. Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of
    nausea PSYCHOPHARMACOLOGY 166 (2): 156-162 MAR 2003
  210. Croxford JL Therapeutic potential of cannabinoids in CNS disease CNS DRUGS 17 (3): 179-202 2003
  211. Razdan RK, Mahadevan A Recent advances in the synthesis of endocannabinoid related ligands CHEM PHYS LIPIDS 121 (1-2): 21-33 DEC 31
    2002
  212. Schuel H, Burkman LJ, Lippes J, et al. N-Acylethanolamines in human reproductive fluids CHEM PHYS LIPIDS 121 (1-2): 211-227 DEC 31 2002
  213. Grigorenko E, Kittler J, Clayton C, et al. Assessment of cannabinoid induced gene changes: tolerance and neuroprotection CHEM PHYS
    LIPIDS 121 (1-2): 257-266 DEC 31 2002
  214. Fowler CJ Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents - Non-psychoactive cannabinoids, 'entourage'
    compounds and inhibitors of N-acyl ethanolarnine breakdown as therapeutic strategies to avoid pyschotropic effects BRAIN RES REV 41 (1): 26-
    43 JAN 2003
  215. Maccarrone M, Finazzi-Agro A Endocannabinoids and their actions VITAM HORM 65: 225-255 2002
  216. Mechoulam R, Parker LA, Gallily R Cannabidiol: An overview of some pharmacological aspects J CLIN PHARMACOL 42 (11): 11S-19S Suppl.
    S NOV 2002
  217. Gonzalez R, Carey C, Grant I Nonacute (Residual) neuropsychological effects of cannabis use: A qualitative analysis and systematic review J
    CLIN PHARMACOL 42 (11): 48S-57S Suppl. S NOV 2002
  218. Parmentier-Batteur S, Jin KL, Mao XO, et al. Increased severity of stroke in CB1 cannabinoid receptor knock-out mice J NEUROSCI 22 (22):
    9771-9775 NOV 15 2002
  219. van der Stelt M, Veldhuis WB, Maccarrone M, et al. Acute neuronal injury, excitotoxicity, and the endocannabinoid system MOL NEUROBIOL
    26 (2-3): 317-346 OCT-DEC 2002
  220. Grundy RI The therapeutic potential of the cannabinoids in neuroprotection EXPERT OPIN INV DRUG 11 (10): 1365-1374 OCT 2002
  221. Costa B, Conti S, Giagnoni G, et al. Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation:
    inhibition of nitric oxide and cyclo-oxygenase systems BRIT J PHARMACOL 137 (4): 413-420 OCT 2002
  222. del Pulgar TG, de Ceballos ML, Guzman M, et al. Cannabinoids protect astrocytes from ceramide-induced apoptosis through the
    phosphatidylinositol 3-kinase/protein kinase B pathway J BIOL CHEM 277 (39): 36527-36533 SEP 27 2002
  223. Romero J, Lastres-Becker I, de Miguel R, et al. The endogenous cannabinoid system and the basal ganglia: biochemical, pharmacological,
    and therapeutic aspects PHARMACOL THERAPEUT 95 (2): 137-152 AUG 2002
  224. Guzman M, Sanchez C, Galve-Roperh I Cannabinoids and cell fate PHARMACOL THERAPEUT 95 (2): 175-184 AUG 2002
  225. Sarafian TA, Kouyoumjian S, Tashkin D, et al. Synergistic cytotoxicity of Delta(9)-tetrahydrocannabinol and butylated hydroxyanisole TOXICOL
    LETT 133 (2-3): 171-179 JUL 21 2002
  226. Behl C, Moosmann B Antioxidant neuroprotection in Alzheimer's disease as preventive and therapeutic approach FREE RADICAL BIO MED 33
    (2): 182-191 JUL 15 2002
  227. Mechoulam R Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression PROSTAG
    LEUKOTR ESS 66 (2-3): 93-99 FEB-MAR 2002
  228. Mauler F, Mittendorf J, Horvath E, et al. Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-
    trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties J PHARMACOL EXP THER 302
    (1): 359-368 JUL 2002
  229. Behl C, Moosmann B Oxidative nerve cell death in Alzheimer's disease and stroke: Antioxidants as neuroprotective compounds BIOL CHEM
    383 (3-4): 521-536 MAR-APR 2002
  230. Parker LA, Mechoulam R, Schlievert C Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog
    suppress nausea in an experimental model with rats NEUROREPORT 13 (5): 567-570 APR 16 2002
  231. Lambert DM, Vandevoorde S, Jonsson KO, et al. The palmitoylethanolamide family: A new class of anti-inflammatory agents? CURR MED
    CHEM 9 (6): 663-674 MAR 2002
  232. Mechoulam R, Panikashvili D, Shohami E Cannabinoids and brain injury: therapeutic implications TRENDS MOL MED 8 (2): 58-61 FEB 2002
  233. Yu XB, Shacka JJ, Eells JB, et al. Erythropoietin receptor signalling is required for normal brain development DEVELOPMENT 129 (2): 505-516
    JAN 2002
  234. Marsicano G, Moosmann B, Hermann H, et al. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid
    receptor CB1 J NEUROCHEM 80 (3): 448-456 FEB 2002
  235. Grundy RI, Rabuffetti M, Beltramo M Cannabinoids and neuroprotection MOL NEUROBIOL 24 (1-3): 29-51 AUG-DEC 2001
  236. Perron RR, Tyson RL, Sutherland GR Delta(9)-Tetrahydrocannabinol increases brain temperature and inverts circadian rhythms
    NEUROREPORT 12 (17): 3791-3794 DEC 4 2001
  237. Bisogno T, Hanus L, De Petrocellis L, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and
    on the cellular uptake and enzymatic hydrolysis of anandamide BRIT J PHARMACOL 134 (4): 845-852 OCT 2001
  238. Abood ME, Rizvi G, Sallapudi N, et al. Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against
    excitotoxicity NEUROSCI LETT 309 (3): 197-201 AUG 31 2001
  239. van der Stelt M, Veldhuis WB, Bar PR, et al. Neuroprotection by Delta(9)-tetrahydrocannabinol, the main active compound in marijuana,
    against ouabain-induced in vivo excitotoxicity J NEUROSCI 21 (17): 6475-6479 SEP 1 2001
  240. Chen M, Fernandez HL Alzheimer movement re-examined 25 years later: Is it a "disease" or a senile condition in medical nature? FRONT
    BIOSCI 6: E30-E40 AUG 2001
  241. Porter AC, Felder CC The endocannabinoid nervous system: unique opportunities for therapeutic intervention PHARMACOL THERAPEUT 90
    (1): 45-60 APR 2001
  242. Hampson AJ, Grimaldi M Cannabinoid receptor activation and elevated cyclic AMP reduce glutamate neurotoxicity EUR J NEUROSCI 13 (8):
    1529-1536 APR 2001
  243. Glass M The role of cannabinoids in neurodegenerative diseases PROG NEURO-PSYCHOPH 25 (4): 743-765 MAY 2001
  244. Lambert DM, Vandevoorde S, Diependaele G, et al. Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice
    EPILEPSIA 42 (3): 321-327 MAR 2001
  245. Guzman M, Sanchez C, Galve-Roperh I Control of the cell survival/death decision by cannabinoids J MOL MED-JMM 78 (11): 613-+ 2001
  246. Maccarrone M, Attina M, Cartoni A, et al. Gas chromatography-mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral
    human brain and human cells in culture J NEUROCHEM 76 (2): 594-601 JAN 2001
  247. Williamson EM, Evans FJ Cannabinoids in clinical practice DRUGS 60 (6): 1303-1314 DEC 2000
  248. Braida D, Pozzi M, Sala M CP 55,940 protects against ischemia-induced electroencephalographic flattening and hyperlocomotion in
    Mongolian gerbils NEUROSCI LETT 296 (2-3): 69-72 DEC 22 2000
  249. Moosmann B, Behl C Dietary phenols: Antioxidants for the brain? Commentary NUTR NEUROSCI 3 (1): 1-10 2000
  250. Carriot F, Sasco AJ Cannabis and cancer REV EPIDEMIOL SANTE 48 (5): 473-483 OCT 2000
  251. Tchilibon S, Mechoulam R Synthesis of a primary metabolite of cannabidiol ORG LETT 2 (21): 3301-3303 OCT 19 2000
  252. Pertwee RG Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and
    development EXPERT OPIN INV DRUG 9 (7): 1553-1571 JUL 2000
  253. Malfait AM, Gallily R, Sumariwalla PF, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in
    murine collagen-induced arthritis P NATL ACAD SCI USA 97 (17): 9561-9566 AUG 15 2000
  254. Favit A, Grimaldi M, Alkon DL Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway J
    NEUROCHEM 75 (3): 1258-1263 SEP 2000
  255. Smith PF Cannabis on the brain: Is it neurotoxic or neuroprotective? NEW ZEAL J PSYCHOL 29 (1): 37-40 JUN 2000
  256. Jin KL, Mao XO, Goldsmith PC, et al. CB2 cannabinoid receptor induction in experimental stroke ANN NEUROL 48 (2): 257-261 AUG 2000
  257. Sevcik J, Masek K Potential role of cannabinoids in Parkinson's disease DRUG AGING 16 (6): 391-395 JUN 2000
  258. Chen YQ, Buck J Cannabinoids protect cells from oxidative cell death: A receptor-independent mechanism J PHARMACOL EXP THER 293 (3):
    807-812 JUN 2000
  259. Kunos G, Jarai Z, Varga K, et al. Cardiovascular effects of endocannabinoids - the plot thickens PROSTAG OTH LIPID M 61 (1-2): 71-84 APR
    2000
  260. Galve-Roperh I, Sanchez C, Cortes ML, et al. Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and
    extracellular signal-regulated kinase activation NAT MED 6 (3): 313-319 MAR 2000
  261. Klein M, Calderon S, Hayes B Abuse liability assessment of neuroprotectants ANN NY ACAD SCI 890: 515-525 1999
  262. Pertwee RG Neuropharmacology and therapeutic potential of cannabinoids ADDICT BIOL 5 (1): 37-46 JAN 2000
  263. Sinor AD, Irvin SM, Greenberg DA Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats NEUROSCI LETT 278 (3):
    157-160 JAN 14 2000
  264. Grotenhermen F The effects of cannabis and THC FORSCH KOMPLEMENTMED 6: 7-11 Suppl. 3 OCT 1999
  265. Jarai Z, Wagner JA, Varga K, et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2
    receptors P NATL ACAD SCI USA 96 (24): 14136-14141 NOV 23 1999
  266. Greenberg DA Cannabinoids and neuroprotection in stroke DRUG NEWS PERSPECT 12 (8): 458-462 OCT 1999
  267. Di Marzo V, Bisogno T, De Petrocellis L, et al. Cannabimimetic fatty acid derivatives: The anandamide family and other 'endocannabinoids'
    CURR MED CHEM 6 (8): 721-744 AUG 1999
  268. Pop E Cannabinoids, endogenous ligands and synthetic analogs CURR OPIN CHEM BIOL 3 (4): 418-425 AUG 1999
  269. McPartland JM, Pruitt PL Side effects of pharmaceuticals not elicited by comparable herbal medicines: The case of tetrahydrocannabinol and
    marijuana ALTERN THER HEALTH M 5 (4): 57-62 JUL 1999
  270. Sarafian TA, Magallanes JAM, Shau HY, et al. Oxidative stress produced by Marijuana smoke - An adverse effect enhanced by cannabinoids
    AM J RESP CELL MOL 20 (6): 1286-1293 JUN 1999
  271. Schneider U, Muller-Vahl KR, Emrich HM Cannabis and endogenous cannabinoid/anandamide-system: neurobiological aspects in psychiatry
    MED WELT 50 (3): 114-119 MAR 1999
  272. Nagayama T, Sinor AD, Simon RP, et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures J
    NEUROSCI 19 (8): 2987-2995 APR 15 1999
  273. Consroe P.  Brain cannabinoid systems as targets for the therapy of neurological disorders. NEUROBIOL DIS 5 (6): 534-551 DEC 1998
  274. A synthetic cannabinoid, CP55940, inhibits lipopolysaccharide-induced cytokine mRNA expression in a cannabinoid receptor-independent
    mechanism in rat cerebellar granule cells Author(s): Chiba T, Ueno S, Obara Y, et al. Source: JOURNAL OF PHARMACY AND
    PHARMACOLOGY Volume: 63 Issue: 5 Pages: 636-647 Published: MAY 2011
  275. Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress,
    and cell death Mukhopadhyay, P., Rajesh, M., Horváth, B., Bátkai, S., Park, O., Tanchian, G., Gao, R.Y., (...), Pacher, P. 2011Free Radical
    Biology and Medicine 50 (10) , pp. 1368-1381
  276. Cannabidiol causes activated hepatic stellate cell death through a mechanism of endoplasmic reticulum stress-induced apoptosis Lim, M.P.,
    Devi, L.A., Rozenfeld, R. 2011Cell Death and Disease 2 (6) , art. no. e170
  277. Psychotropic and nonpsychotropic cannabis derivatives inhibit human h5-HT 3A receptors through a receptor desensitization-dependent
    mechanism Xiong, W., Koo, B.-N., Morton, R., Zhang, L. 2011Neuroscience 184 , pp. 28-37
  278. Cannabioids and the brain: Review of MRI studies | [Wirkung von cannabinoiden auf das gehirn: Ein überblick über MRI befunde] Hermann, D.
    2011Sucht 57 (3) , pp. 161-171
  279. Administration of cannabidiol and imipramine induces antidepressant-like effects in the forced swimming test and increases brain-derived
    neurotrophic factor levels in the rat amygdala Réus, G.Z., Stringari, R.B., Ribeiro, K.F., Luft, T., Abelaira, H.M., Fries, G.R., Aguiar, B.W., (...),
    Quevedo, J. 2011Acta Neuropsychiatrica 23 (5) , pp. 241-248 0   View at publisher | |          
  280. Cannabidiol reduces brain damage and improves functional recovery after acute hypoxia-ischemia in newborn pigs Lafuente, H., Alvarez, F.J.,
    Pazos, M.R., Alvarez, A., Rey-Santano, M.C., Mielgo, V., Murgia-Esteve, X., (...), Martinez-Orgado, J. 2011Pediatric Research 70 (3) , pp. 272-
    277 1   View at publisher | |   Show abstract  | Related documents             
  281. Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease Sagredo, O., Pazos, M.R., Satta,
    V., Ramos, J.A., Pertwee, R.G., Fernández-Ruiz, J. 2011Journal of Neuroscience Research 89 (9) , pp. 1509-1518 2   View at publisher | |   
    Show abstract  | Related documents             
  282. Prospects for cannabinoid therapies in basal ganglia disorders Fernández-Ruiz, J., Moreno-Martet, M., Rodríguez-Cueto, C., Palomo-Garo, C.,
    Gõmez-Cañas, M., Valdeolivas, S., Guaza, C., (...), Ramos, J.A. 2011British Journal of Pharmacology 163 (7) , pp. 1365-1378 2   View at
    publisher | |   Show abstract  | Related documents  
  283. Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice
    Kozela, E., Lev, N., Kaushansky, N., Eilam, R., Rimmerman, N., Levy, R., Ben-Nun, A., (...), Vogel, Z. 2011British Journal of Pharmacology 163
    (7) , pp. 1507-1519 2   View at publisher | |   Show abstract  | Related documents             
  284. The dual neuroprotective-neurotoxic profile of cannabinoid drugs Sarne, Y., Asaf, F., Fishbein, M., Gafni, M., Keren, O. 2011British Journal of
    Pharmacology 163 (7) , pp. 1391-1401 1   View at publisher | |   Show abstract  | Related documents            
  285. result20 Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects Russo, E.B. 2011British Journal of
    Pharmacology 163 (7) , pp. 1344-1364 6   View at publisher | |   Show abstract  | Related documents             
  286. Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with parkinson's Little, J.P., Villanueva, E.B., Klegeris,
    A. 2011Mini-Reviews in Medicinal Chemistry
  287. The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis Baker, D.,
    Pryce, G., Jackson, S.J., Bolton, C., Giovannoni, G. 2012Multiple Sclerosis and Related Disorders 1 (2) , pp. 64-75 0   View at publisher | |   
    Show abstract  | Related documents      
  288. result2 Cannabinoids: Novel medicines for the treatment of Huntington's disease Sagredo, O., Ruth Pazos, M., Valdeolivas, S., Fernández-Ruiz,
    J. 2012Recent Patents on CNS Drug Discovery 7 (1) , pp. 41-48 1   View at publisher | |   Show abstract  | Related documents             
  289. result3 Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders
    Fagherazzi, E.V., Garcia, V.A., Maurmann, N., Bervanger, T., Halmenschlager, L.H., Busato, S.B., Hallak, J.E., (...), Schröder, N.
    2012Psychopharmacology 219 (4) , pp. 1133-1140 0   View at publisher | |   Show abstract  | Related documents             
  290. result4 Natural prenylated resveratrol analogs arachidin-1 and -3 demonstrate improved glucuronidation profiles and have affinity for
    cannabinoid receptors Brents, L.K., Medina-Bolivar, F., Seely, K.A., Nair, V., Bratton, S.M., Opo-Olazabal, L., Patel, R.Y., (...), Radominska-
    Pandya, A. 2012Xenobiotica 42 (2) , pp. 139-156 0   View at publisher | |   Show abstract  | Related documents       
  291. result5 Effect of ion pairing on in vitro transcorneal permeability of a Δ 9-tetrahydrocannabinol prodrug: Potential in glaucoma therapy
    Hingorani, T., Gul, W., Elsohly, M., Repka, M.A., Majumdar, S. 2012Journal of Pharmaceutical Sciences 101 (2) , pp. 616-626 0   View at
    publisher | |   Show abstract  | Related documents             
  292. result6 Contrasting protective effects of cannabinoids against oxidative stress and amyloid-β evoked neurotoxicity in vitro Harvey, B.S., Ohlsson,
    K.S., Mååg, J.L.V., Musgrave, I.F., Smid, S.D. 2012NeuroToxicology 33 (1) , pp. 138-146 0   View at publisher | |   Show abstract  | Related
    documents             
  293. result7 Cannabidiol injected into the bed nucleus of the stria terminalis reduces the expression of contextual fear conditioning via 5-HT 1A
    receptors Gomes, F.V., Reis, D.G., Alves, F.H.F., Corrêa, F.M.A., Guimarães, F.S., Resstel, L.B.M. 2012Journal of Psychopharmacology 26 (1) ,
    pp. 104-113 1   View at publisher | |   Show abstract  | Related documents             
  294. result8 Phytocannabinoids as novel therapeutic agents in CNS disorders Hill, A.J., Williams, C.M., Whalley, B.J., Stephens, G.J.
    2012Pharmacology and Therapeutics 133 (1) , pp. 79-97 0   View at publisher | |   Show abstract  | Related documents             
  295. result9 Neuroprotective agents: Cannabinoids Sánchez, A.J., García-Merino, A. 2012Clinical Immunology 142 (1) , pp. 57-67 0   View at
    publisher | |   Show abstract  | Related documents             
  296. result10 Targeting the endocannabinod system to limit myocardial and cerebral ischemic and reperfusion injury Tuma, R.F., Steffens, S.
    2012Current Pharmaceutical Biotechnology 13 (1) , pp. 46-58 0   View at publisher | |   Show abstract  | Related documents             
  297. result11 Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement Esposito,
    G., Scuderi, C., Valenza, M., Togna, G.I., Latina, V., de Filippis, D., Cipriano, M., (...), Steardo, L. 2011PLoS ONE 6 (12) , art. no. e28668 0   
    View at publisher | |   Show abstract  | Related documents             
  298. result12 Immunomodulatory properties of kappa opioids and synthetic cannabinoids in HIV-1 neuropathogenesis Hu, S., Sheng, W.S., Rock, R.
    B. 2011Journal of Neuroimmune Pharmacology 6 (4) , pp. 528-539 1   View at publisher | |   Show abstract  | Related documents           
  299. result13 The multiplicity of action of cannabinoids: Implications for treating neurodegeneration Gowran, A., Noonan, J., Campbell, V.A.
    2011CNS Neuroscience and Therapeutics 17 (6) , pp. 637-644 3